Trying our Patients

FromI AM BIO

Start listening View podcast show

Trying our Patients

FromI AM BIO

ratings:

Length:

36 minutes

Released:

Mar 9, 2020

Format:

Podcast episode

Description

As genetic sequencing gives scientists new tools to hone in on medical mysteries, Washington politicians flirt dangerously with policies that would stymie the genomic revolution while giving patients scant pricing relief at the pharmacy counter.

Hosted by Jim Greenwood.

Released:

Mar 9, 2020

Format:

Podcast episode

Titles in the series (100)

Powerful stories of biotechnology breakthroughs, the people they help, and the global problems they solve. Hosted by BIO President & CEO Dr. Michelle McMurry-Heath.

Skip carousel

Destroying COVID's Genome: Alnylam Pharmaceuticals, which take its name from the center and brightest star in Orion’s Belt, is working on an RNAi therapy to destroy the genome of the novel coronavirus — and with it, its ability to replicate and kill. Hosted by Jim Greenwood. by I AM BIO
39 min listen
“Herd” Immunity (Redux): Biotech companies are working feverishly to develop antibody therapies to provide short-term protection against COVID-19. But what if the novel coronavirus mutates and outwits traditional monoclonal antibodies? Well, that’s where the super cows come in. Hosted by Jim Greenwood. by I AM BIO
36 min listen
The Antibody Test Shortage: Only antibody testing can tell us who has been infected and recovered from coronavirus and when it might be safe to return to work. There’s a massive global shortage of these tests, and a Maryland biotech is racing to bolster the U.S. supply. Hosted by Jim Greenwood. by I AM BIO
27 min listen
An Alternative to Flying Dirty: While Swedish climate activist Greta Thunberg has kindled a global dialogue about the ravages of climate change and the role of airline emissions, a Colorado biotech is putting forward a jaw-dropping alternative to flight shaming: actual jet fuel with no carbon footprint. Hosted by Jim Greenwood. by I AM BIO
40 min listen
COVID-19 Could Generate 1st Computerized Vaccine: Futuristic biotech Moderna is the first to clinically test a coronavirus vaccine, created in weeks using only the virus’ genetic code. The company’s messenger RNA breakthrough may be just in time as a former CDC director warns that animal viruses spilling over to humans is the new normal. Hosted by Jim Greenwood. by I AM BIO
60 min listen
First Dose: One day before 16-year-old Izzy Thorpe-Wall takes her first dose of Vertex’s stunning Cystic Fibrosis breakthrough, Thorpe and her mother, Clare, open up about their emotional journey and one brave girl’s determination to stay healthy long enough to meet this day of her dreams. Hosted by Jim Greenwood. by I AM BIO
43 min listen
COVID-19: We Were Warned: For years, leaders on the Bipartisan Commission on Biodefense told Congress and the White House that it wasn’t a matter of if, but when, a pandemic would happen. Exploring the panel’s unheeded recommendations can give the United States a blueprint for what to do going forward to protect us from the coronavirus and future threats. Hosted by Jim Greenwood. by I AM BIO
50 min listen
Going Viral: Vir Biotechnology CEO George Scangos is the scientist selected by his peers to lead the biotechnology industry’s efforts to mitigate and ultimately end the pandemic. He explains how and why the novel coronavirus is so contagious and potentially dangerous to millions. Hosted by Jim Greenwood. by I AM BIO
23 min listen
COVID-19’s True Origins: There's a joke among ecological health scientists that if “you don’t believe one person can change the world, try eating an undercooked bat.” However, what EcoHealth Alliance’s Dr. William Karesh — a world-renowned expert on zoonotic disease transmission — reveals about the trend line for animal-to-human viral transmission is no laughing matter. Hosted by Jim Greenwood. by I AM BIO
39 min listen
Coronavirus Lung Treatment Could be Ready In Weeks: Regeneron’s rheumatoid arthritis drug shows promise to treat coronavirus-related lung syndrome and stop the inflammation that leads to death. The company also expects to test a preventative antibody shot in June. Hosted by Jim Greenwood. by I AM BIO
40 min listen
“Herd” Immunity: Biotech companies are working feverishly to develop antibody therapies to provide short-term protection against COVID-19. But what if the novel coronavirus mutates and outwits traditional monoclonal antibodies? Well, that’s where the super cows come in. Hosted by Jim Greenwood. by I AM BIO
36 min listen
New Trailer with Dr. Michelle: The I AM BIO podcast with host Dr. Michelle McMurry-Heath explores the search for biotechnology breakthroughs and our progress in ending the pandemic, helping patients and carrying the mantle for science and sustainability. by I AM BIO
2 min listen
Biotech's Finest Hour (Redux): As the world waits for biotechnology to deliver COVID-19 treatments and a vaccine, Ambassador Deborah Birx tells BIO’s scientists: “Expectations are high because you’ve delivered for us before and I know that you can deliver for us again.” BIO chairman Jeremy Levin, a biotech pioneer, explains how the industry will rise to meet this moment. Hosted by Jim Greenwood. by I AM BIO
48 min listen
What Can Iceland Tell Us About COVID?: The people of Iceland — a country of 360,000 — eagerly volunteered for genetic research on how the coronavirus affects a homogeneous population. Amgen’s work in the Land of Fire and here at home could deliver answers and antibodies to help mitigate the pandemic threat. Hosted by Jim Greenwood. by I AM BIO
32 min listen
COVID’s Essential Work: The physician-wife of Roivant Sciences CEO Vivek Ramaswamy rushed back to the front lines at the pandemic’s peak — less than a month after giving birth to the couple’s first son. Meanwhile, dad cared for their newborn while testing a promising therapeutic that seeks to overcome deadly cytokine storms caused by the novel coronavirus. Hosted by Jim Greenwood. by I AM BIO
30 min listen
Biotech’s Finest Hour: As the world waits for biotechnology to deliver COVID-19 treatments and a vaccine, Ambassador Deborah Birx tells BIO’s scientists: “Expectations are high because you’ve delivered for us before and I know that you can deliver for us again.” BIO chairman Jeremy Levin, a biotech pioneer, explains how the industry will rise to meet this moment. Hosted by Jim Greenwood. by I AM BIO
53 min listen
Trying our Patients: As genetic sequencing gives scientists new tools to hone in on medical mysteries, Washington politicians flirt dangerously with policies that would stymie the genomic revolution while giving patients scant pricing relief at the pharmacy counter. Hosted by Jim Greenwood. by I AM BIO
36 min listen
COVID-19’s True Origins (Redux): There's a joke among ecological health scientists that if “you don’t believe one person can change the world, try eating an undercooked bat.” However, what EcoHealth Alliance’s Dr. William Karesh — a world-renowned expert on zoonotic disease transmission — reveals about the trend line for animal-to-human viral transmission is no laughing matter. Hosted by Jim Greenwood. by I AM BIO
39 min listen
Superbuggin’: Incurable gonorrhea and the deadly hospital superbug C. diff offer a frightening window into the gathering public health menace of antibiotic resistance. If society doesn’t wake up and tackle the problem, we could be headed toward a calamity on the magnitude of climate change. Hosted by Jim Greenwood. by I AM BIO
28 min listen
COVID & the Plastics Problem: Fear and misinformation about how the coronavirus is transmitted has led to dangerous backsliding in society’s efforts to address plastic pollution. But we don’t have to lose this battle to win the COVID war. A Georgia biotech is first to market with a green biopolymer material that looks and feels like plastic but dissolves in ocean water. Hosted by Jim Greenwood. by I AM BIO
32 min listen
COVID X-FACTOR: The diversity of our adaptive immune system is why people are reacting so differently to the novel coronavirus. No two people present the virus the exact same way to their immune systems. We’ve evolved in this way as humans to ensure no virus can eradicate our species. Hosted by Jim Greenwood. by I AM BIO
32 min listen
Cancer in the COVID Era: Overcrowded hospitals during the pandemic can pose treatment challenges for patients with other serious illnesses. As Kite Pharma CEO Christi Shaw says, “Cancer doesn’t stop in a crisis.” Neither do her company’s employees, who go to extraordinary lengths to get personalized CAR-T treatments to patients around the world. Hosted by Jim Greenwood. by I AM BIO
20 min listen
Vaccines are a Virtue: As biotech researchers work around the clock on a covid vaccine, ill-informed, anti-science anti-vaxxers must be denounced and excoriated in the public square. BIO’s head of infectious disease policy Phyllis Arthur administers a vital dose of vaccine education, because none of us is safe until we all are. Hosted by Jim Greenwood. by I AM BIO
33 min listen
Sickle Cell Saviors: Need a dose of inspiration in a time of national tragedy? A remarkable biotech breakthrough from Global Blood Therapeutics offers fresh hope to patients living with sickle-cell disease. Hosted by Jim Greenwood. by I AM BIO
62 min listen
The Other Pandemic: Beating “Nightmare Bugs” (Part 2 of 2): Viral pandemics can lead to secondary bacterial infections that kill millions, Dr. Anthony Fauci concluded after studying the 1918 Spanish flu. A century later, COVID and antibiotic resistance are proving to be a lethal combination. What are the biopharma industry and Congress doing to keep your loved ones safe from superbugs? Hosted by Jim Greenwood. by I AM BIO
32 min listen
Vaccine Velocity: How can global nonprofits like the Center for Epidemic Preparedness Innovations (CEPI) deliver a safe and effective vaccine against the novel coronavirus in just 12 to 18 months when the world record for vaccine approval is four years? CEPI CEO Richard Hatchett, a 9/11 hero, says it’s all about smart planning. By the time governments give the green light on the safety and efficacy of a covid vaccine, manufacturer capacity will be pre-scaled up and able to quickly churn out doses by the tens or hundreds of millions. Hosted by Jim Greenwood. by I AM BIO
33 min listen
BONUS: Breaking Barriers in Trade: A Conversation with Dr. Ngozi Okonjo-Iweala: We are on summer break as we work to bring you another exciting season this fall. So, for the next few weeks we’re sharing some of our favorite sessions from the June 2021 BIO Digital. Today, check out our session Breaking Barriers in Trade: A Conversation with Dr. Ngozi Okonjo-Iweala, Director-General, World Trade Organization. Speaker: Dr. Ngozi Okonjo-Iweala, World Trade Organization by I AM BIO
33 min listen
Respiratory Rescue?: The engine powering Maryland vaccine maker Novavax is a recombinant nanoparticle platform that is impressing vaccinologists as well as government and nonprofit funders. Learn about the innovative biotech generating big buzz in the global covid vaccine race. by I AM BIO
28 min listen
Can We Pass This COVID Test?: Millions of travelers ignored public health warnings and packed into airports over the holidays to see their loved ones. As a result, U.S. hospitals are bracing for the deadliest COVID surge yet this month. Meanwhile, Sherlock Biosciences, which has already made history once with CRISPR, seeks to do so again with an inexpensive, accurate home test that could be a global game-changer. by I AM BIO
36 min listen
Deep Diving for COVID Cures: By studying our earliest evolutionary ancestors in the ocean, marine biotech researchers are gaining fresh insights about everything from anti-virals to coronavirus nasal swab testing to the inner workings of our adaptive immune systems. Learn what sea sponges, lugworms and sharks can teach us about improving human health during this crisis. Hosted by Jim Greenwood. by I AM BIO
43 min listen

More Episodes from I AM BIO

Skip carousel

Listener takeover: Your Biotech Questions Answered: YOU asked, and we answered. In this episode, we had our experts on standby to answer questions from you, our listeners. We discuss topics ranging from the safety of genetically modified foods (GMOs), to the new era of personalized medicine, feeding the world by 2050, and even what makes start-up companies attractive to investors. by I AM BIO
21 min listen
Editing Cells Within the Body—a New CRISPR Frontier: With its potential to expand the horizons of what’s possible for patients, CRISPR is the new darling of biotech. Reaching an important milestone in 2023 with the FDA approval of a sickle cell treatment using CRISPR, the technology is poised to break new barriers for treating patients in the near future. In this episode we talk with two companies working together on the next generation of CRISPR: editing cells within the body. We discuss the progress and the challenge in making this breakthrough a reality. by I AM BIO
21 min listen
Biotech is Climate Tech: Biotech companies are addressing climate change through innovation—from carbon neutral facilities to agricultural innovations to reduce greenhouse gas emissions. BIO was on the ground at the COP28 UN Climate Change Conference in Dubai to deliver the message that biotech is climate tech. by I AM BIO
21 min listen
Biotech for our Pets: More than half of U.S. households include pets, but there has been a lack of medical treatments developed specifically for small animals. Biotech companies are working to change that with new treatment options that both borrow from and, potentially, advance human health discoveries. by I AM BIO
28 min listen
What We Know About the Microbiome: The gut microbiome, which consists of trillions of bacteria, viruses, and fungi, plays a crucial role in our health. However, there is still much to learn about this complex ecosystem. On this episode we talk with experts who tell us where the science is—how much we know, and how much we don’t. Two companies, Bloom Science and Seres Therapeutics, are leveraging the microbiome to develop new therapeutics. The potential of the microbiome is vast, and further research and technological advancements will continue to unlock its benefits. by I AM BIO
27 min listen
Is CRISPR the New Sickle Cell Savior?: 2023 ended with an exciting biotech breakthrough for sickle cell patients. A gene-editing therapy using the revolutionary CRISPR technology provides new hope and options for the nearly 100,000 Americans with sickle cell disease. In this episode, we talk with the company behind one of the life-changing therapies, CASGEVY, and speak with two advocates for sickle cell patients. by I AM BIO
25 min listen
“On My Own”—Desperate to Stop a Resistant Bacterial Infection (REDUX): Bradley Burnam woke up one morning, looked in the mirror and found one ear twice it’s normal size and his face swollen and discolored. He would spend the next several years in and out of the hospital fighting a relentless infection that would not respond to available treatments. The experience took him from patient to mad scientist, to biotech company founder. In this episode, Bradley takes us through his desperate journey to find a cure. We also talk with the leader of an organization helping to get more antimicrobials to the marketplace. by I AM BIO
28 min listen
The Synbio Revolution is Here (REDUX): Innovative companies are using synthetic biology to engineer organisms and create new materials that could transform every sector of our economy, from health care to food and energy production. Those companies say we’ve entered a synbio revolution, and it holds potential to improve the health of people and our planet. In this episode, we talk with three synbio experts about how this convergence of genetic engineering, computer science and other scientific disciplines is making our world more sustainable. by I AM BIO
26 min listen
How Biotechs Survive the Valley of Death (REDUX): For biotech companies, the valley of death describes the difficult path from initial discovery to FDA approval and commercialization. It's a treacherous journey—one that even promising innovations often don't complete. Adequate funding, regulatory hurdles and the immense complexity of the biotech landscape are among the never-ending challenges faced by early stage biotechs. In this episode we talk with two biotech executives about what it’s like to struggle and survive in this rough-and-tumble industry. by I AM BIO
25 min listen
Biotech Women Striking at the Glass Ceiling (REDUX): The biotech industry offers unique opportunities for women to advance as executives and entrepreneurs. There are headwinds, however, including unequal access to venture capital. In this episode, we talk with three executives who are part of a wave of women-led companies in biotech. Our guests speak to why women’s leadership matters and the barriers that remain to breaking the glass ceiling. They also tell us about a new networking initiative—the biotech sisterhood—to catalyze women’s success in corporate leadership and mentor the next generation of women executives. by I AM BIO
25 min listen
We Need Bees. Bees Need Biotech. (REDUX): Bees and other pollinators are critical to our survival, with one out of every three bites of food we eat depending on pollination to produce. That’s why reports of a decline in bee populations and rising threats from pests, viruses and environmental pressures, including climate change, are alarming. In this episode we talk with an expert on bees and other pollinators about how bees are doing and why it’s important to save them. We also talk with two biotech leaders whose companies are working to improve bee health through development of innovative treatments for some of the worst threats faced by bees. by I AM BIO
27 min listen
The Horseshoe Crab Saved Us. Can We Save the Horseshoe Crab? (REDUX): The horseshoe crab has endured for over 450 million years. It has survived several mass extinctions including the one that killed off the dinosaurs. One reason for their incredible resiliency is their ability to fend off bacterial infection. Their blood contains cells that clot around invading bacteria, thereby protecting them from the attacking toxins. In this episode we talk with three experts about how this animal’s unique blue blood has become essential to modern medicine. We also talk about why horseshoe crab populations are dwindling, and what biotech is doing to address the shortfall. by I AM BIO
28 min listen
“On My Own”—Desperate to Stop a Resistant Bacterial Infection: Bradley Burnam woke up one morning, looked in the mirror and found one ear twice it’s normal size and his face swollen and discolored. He would spend the next several years in and out of the hospital fighting a relentless infection that would not respond to available treatments. The experience took him from patient to mad scientist, to biotech company founder. In this episode, Bradley takes us through his desperate journey to find a cure. We also talk with the leader of an organization helping to get more antimicrobials to the marketplace. by I AM BIO
28 min listen
The Synbio Revolution is Here: Innovative companies are using synthetic biology to engineer organisms and create new materials that could transform every sector of our economy, from health care to food and energy production. Those companies say we’ve entered a synbio revolution, and it holds potential to improve the health of people and our planet. In this episode, we talk with three synbio experts about how this convergence of genetic engineering, computer science and other scientific disciplines is making our world more sustainable. by I AM BIO
26 min listen
How Biotechs Survive the Valley of Death: For biotech companies, the valley of death describes the difficult path from initial discovery to FDA approval and commercialization. It's a treacherous journey—one that even promising innovations often don't complete. Adequate funding, regulatory hurdles and the immense complexity of the biotech landscape are among the never-ending challenges faced by early stage biotechs. In this episode we talk with two biotech executives about what it’s like to struggle and survive in this rough-and-tumble industry. by I AM BIO
25 min listen
Biotech Women Striking at the Glass Ceiling: The biotech industry offers unique opportunities for women to advance as executives and entrepreneurs. There are headwinds, however, including unequal access to venture capital. In this episode, we talk with three executives who are part of a wave of women-led companies in biotech. Our guests speak to why women’s leadership matters and the barriers that remain to breaking the glass ceiling. They also tell us about a new networking initiative—the biotech sisterhood—to catalyze women’s success in corporate leadership and mentor the next generation of women executives. by I AM BIO
25 min listen
We Need Bees. Bees Need Biotech.: Bees and other pollinators are critical to our survival, with one out of every three bites of food we eat depending on pollination to produce. That’s why reports of a decline in bee populations and rising threats from pests, viruses and environmental pressures, including climate change, are alarming. In this episode we talk with an expert on bees and other pollinators about how bees are doing and why it’s important to save them. We also talk with two biotech leaders whose companies are working to improve bee health through development of innovative treatments for some of the worst threats faced by bees. by I AM BIO
27 min listen
The Horseshoe Crab Saved Us. Can We Save the Horseshoe Crab?: The horseshoe crab has endured for over 450 million years. It has survived several mass extinctions including the one that killed off the dinosaurs. One reason for their incredible resiliency is their ability to fend off bacterial infection. Their blood contains cells that clot around invading bacteria, thereby protecting them from the attacking toxins. In this episode we talk with three experts about how this animal’s unique blue blood has become essential to modern medicine. We also talk about why horseshoe crab populations are dwindling, and what biotech is doing to address the shortfall. by I AM BIO
28 min listen
Stand Up for Science—The Fight Against Misinformation (Redux): Wading through the torrent of information available online is challenging for everyone. It can be hard to know what and whom to believe. We talk with the FDA Commissioner and other leaders on the frontlines of health and science about how to be more aware of false and misleading information, and its risks to our wellbeing and future innovation. And we discuss ways to stand up for science and stop the spread of misinformation. by I AM BIO
26 min listen
Is Space the Next Frontier for Biotech? (Redux): The International Space Station has been orbiting in lower earth since 1998 and has been continually inhabited since November 2000. The ISS was originally conceived as a staging base for future missions into deep space. As it turns out, lower earth orbit is an ideal setting for scientific research, from physics and meteorology to astronomy and the life sciences. In this episode we talk with three scientists whose projects are using lower earth orbit to deepen our knowledge of biotechnology and its benefits for mankind. by I AM BIO
27 min listen
The New Age of CRISPR (Redux): CRISPR has emerged as a powerful tool for altering DNA sequences with incredible precision, opening up new avenues of research into the treatment of disease. In this episode, we explore the science behind CRISPR, as well as its potential. From curing genetic disorders to creating new crop varieties, the possibilities seem endless. Our four guests today are scientists working to push these gene editing tools to the next frontier. by I AM BIO
28 min listen
Accelerating Hope: The Pathway for Cures (Redux): When people were dying from AIDS in the 1980s and 90s, Congress found a way to expedite the drug approval process and saved countless lives. Established in 1992, the Accelerated Approval Program allows the FDA to speed approval of drugs for patients with serious and life-threatening conditions. In this episode we talk with the father of children with a rare disease, a company CEO working to treat rare diseases and two policy experts on Accelerated Approval. by I AM BIO
23 min listen
Why AI and Biotech are BFFs (Redux): The convergence of Artificial Intelligence (AI) and biotechnology has emerged as one of the most exciting and transformative areas of science. Researchers are developing new tools and technology that could bring about breakthroughs to revolutionize the fields of medicine and health care. In this episode, we talk with scientists who are using AI to unlock new possibilities in the search for novel drugs, cures, and treatments. by I AM BIO
22 min listen
Cracking the Code on Pain Relief (Redux): Imagine living with excruciating pain that prevents you from walking or doing the things most of us take for granted. We all experience pain, and 50 million people cope with chronic, debilitating pain. The market for pain therapies is estimated at $74 billion. And yet, investment in new pain and addiction treatments is falling short of what is needed, according to a new BIO report, which shows a 44% decrease in clinical drug programs for pain over the past five years. Our guests on this episode talk about the challenges of living with and treating pain, as well as research and development on new, non-addictive and safer pain therapies. by I AM BIO
26 min listen
Why are Katie Couric and 15K People Headed to Boston?: During the last several decades Boston has become a biotech Mecca, with its Kendall Square attracting more than 120 biotech companies, both large and small. It is called the most innovative square mile on the planet. This June BIO will bring over 15,000 biotech leaders to Boston for its 2023 BIO International Convention. Speakers including award-winning journalist and health advocate, Katie Couric, will talk about how they will “Stand up for Science”—the Convention’s theme. MassBIO CEO, Kendalle Burlin O’Connell joins host, Rachel King in a wide-ranging discussion about how Boston became the largest biotech hub in the world. by I AM BIO
16 min listen
Stand Up for Science—The Fight Against Misinformation: Wading through the torrent of information available online is challenging for everyone. It can be hard to know what and whom to believe. We talk with the FDA Commissioner and other leaders on the frontlines of health and science about how to be more aware of false and misleading information, and its risks to our wellbeing and future innovation. And we discuss ways to stand up for science and stop the spread of misinformation. by I AM BIO
26 min listen
Is Space the Next Frontier for Biotech?: The International Space Station has been orbiting in lower earth since 1998 and has been continually inhabited since November 2000. The ISS was originally conceived as a staging base for future missions into deep space. As it turns out, lower earth orbit is an ideal setting for scientific research, from physics and meteorology to astronomy and the life sciences. In this episode we talk with three scientists whose projects are using lower earth orbit to deepen our knowledge of biotechnology and its benefits for mankind. by I AM BIO
27 min listen
The New Age of CRISPR: CRISPR has emerged as a powerful tool for altering DNA sequences with incredible precision, opening up new avenues of research into the treatment of disease. In this episode, we explore the science behind CRISPR, as well as its potential. From curing genetic disorders to creating new crop varieties, the possibilities seem endless. Our four guests today are scientists working to push these gene editing tools to the next frontier. by I AM BIO
28 min listen
Accelerating Hope: The Pathway for Cures: When people were dying from AIDS in the 1980s and 90s, Congress found a way to expedite the drug approval process and saved countless lives. Established in 1992, the Accelerated Approval Program allows the FDA to speed approval of drugs for patients with serious and life-threatening conditions. In this episode we talk with the father of children with a rare disease, a company CEO working to treat rare diseases and two policy experts on Accelerated Approval. by I AM BIO
23 min listen
Why AI and Biotech are BFFs: The convergence of Artificial Intelligence (AI) and biotechnology has emerged as one of the most exciting and transformative areas of science. Researchers are developing new tools and technology that could bring about breakthroughs to revolutionize the fields of medicine and health care. In this episode, we talk with scientists who are using AI to unlock new possibilities in the search for novel drugs, cures, and treatments. by I AM BIO
22 min listen

Related podcast episodes

Skip carousel

COVID-19 Health Care Breakthroughs – Convalescent Plasma by Newt's World
22 min listen
AstraZeneca Vaccine Is 70% Effective on Average, up to 90% Depending on Dosage by The Daily Dive
20 min listen
Getting Answers on Vaccine Boosters by Deep Background with Noah Feldman
35 min listen
Expert Debate: The Ethics of Consumer Genetic Testing by Focus on Neurology and Psychiatry
1 min listen
Should Black People Get Race Adjustments In Kidney Medicine?: NPR science correspondent Maria Godoy explains the debate around eliminating the race-based kidney health diagnostic tool eGFR. by Short Wave
15 min listen
Pharma and Biotech Daily: Keeping You Informed on the Latest in Healthcare Innovation by Pharma and BioTech Daily
3 min listen
Pharma and Biotech Daily: Bringing You the Latest Breakthroughs in Healthcare by Pharma and BioTech Daily
2 min listen
James A. Geraghty, "Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology" (Cold Springs Harbor Lab Press, 2022): An interview with James A. Geraghty by New Books in Science, Technology, and Society
43 min listen
James A. Geraghty, "Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology" (Cold Springs Harbor Lab Press, 2022): An interview with James A. Geraghty by New Books in Science
43 min listen
Pharma and Biotech Daily: Your Source for the Latest in Medical Breakthroughs by Pharma and BioTech Daily
2 min listen
Influence of Molecular Testing on Influenza Diagnosis: Influenza viruses affect millions of people each year, leading to several hundred thousand hospitalizations and thousands of deaths annually in the U.S. Early antiviral therapy reduces the duration of illness, complications and mortality associated... by Clinical Chemistry Podcast
10 min listen
Biomarkers in the ED - useful or useless - Katrin Hruska: All biomarkers are awesome predictors of badness. Elevated hS-troponins after non-cardiac surgery or an acute exacerbation of COPD are associated with increased mortality. In seemingly healthy people elevated D-dimer levels are associated with... by Coda Change
27 min listen
The Courage to Face COVID and COVID Fascism | Guest: Dr. Peter McCullough | 7/11/22 by Conservative Review with Daniel Horowitz
67 min listen
CEOs double down on voting-rights fight by Apple News Today
11 min listen
Old Drugs, New Disease by Chasing Life
11 min listen
The Race Gap in Clinical Trials by Prognosis: Losing it
16 min listen
The Pharma and Biotech Daily Podcast: Keeping You Informed on the Latest Healthcare Innovations by Pharma and BioTech Daily
2 min listen
Flashback Friday | #236: Our Genetically Modified Future by Macroaggressions
67 min listen
Pharma and Biotech Daily: Your Prescription for Cutting-Edge News by Pharma and BioTech Daily
4 min listen
Breakthrough Rectal Cancer Drug Trial: What It Means For You by Cancer Straight Talk
19 min listen
Why Are So Many Americans Hesitant To Get A COVID-19 Vaccine?: Clinical trials are continuing as drug companies work toward creating a coronavirus vaccine. While hopes for a vaccine remain high, trust in the process to develop one is less so. by Consider This from NPR
13 min listen
New Prevention Options for Alzheimer's Disease: Are They Effective? | Dr. Neal Barnard Live Q&A: New findings suggest an old method for preventing the flu may also help prevent Alzheimer's disease. A study shows that adults who receive a flu vaccine are less likely to develop Alzheimer's disease and dementia. But does level of protection... by The Exam Room by the Physicians Committee
69 min listen
Scientists Fear The Trump Administration Is Putting Politics Before Public Health: From an oversold therapeutic treatment to a quiet change in testing guidance, experts worry the Trump administration is letting politics guide public health. by Consider This from NPR
13 min listen
60 Minutes 12/29 by 60 Minutes
43 min listen
Rarest of Them All: Ultra-Rare Rheumatic Diseases – Part 1: Multisystem autoimmune rheumatic diseases are rare or ultra-rare disorders linked to significant mortality and morbidity. However, with the rise of new technology, including data registries and advanced genetic analysis, rare rheumatic disease... by Rheum Advisor on Air
16 min listen
2019 drug approvals in hematology-oncology: , of the University of Pennsylvania, Philadelphia, joins the podcast to discuss noteworthy drug approvals in hematology-oncology in 2019. Dr. Mintzer and Blood & Cancer host, , of Pennsylvania Hospital, Philadelphia, discuss what these new... by Blood & Cancer
21 min listen
75: 47 Vaccines - Racing Against Time by The Readback
19 min listen
Emerging Trends in Cardiovascular Medicine by FX Medicine Podcast Central
20 min listen
COVID-19 Doesn’t Play Fair: What We Need to Understand About Racial Disparities by WCG Talks Trials
23 min listen
Pharmacy Innovation Leads to Cheaper Rx by Healthcare Americana
28 min listen

Discover this podcast and so much more

Trying our Patients

Trying our Patients

Description

Titles in the series (100)

More Episodes from I AM BIO

Related podcast episodes